Journals / Türk Geriatri Dergisi / 2020 / Cilt: 23 - Sayı: 2

PREDICTING THE RISK OF DYSKINESIA DEVELOPMENT IN PARKINSON’S DISEASE

Pages
224–229
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Dyskinesia was observed in 29% of the patients overall, 24% of the tremor dominant patients, and 35% of the non-tremor dominant patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Parkinson’s Disease is a neurodegenerative disease characterized by motor and non-motor findings.
📊
Key Findings & Data:Parkinson’s Disease is divided into two phenotypes, tremor dominant, and non-tremor dominant.We aimed to investigate and compare the incidence of dyskinesia development and other clinical parameters such as age, gender, disease duration, and treatment between the tremor dominant and non-tremor dominant phenotypes of idiopathic Parkinson’s Disease.Methods: We conducted a retrospective study of 502 patients (183 females, 319 male) with idiopathic Parkinson’s Disease.Results: Two hundred eighty-five (56%) patients had tremor dominant phenotype and 217 (44%) had non-tremor dominant.
💡
Conclusion & Impact:Dyskinesia was observed in 29% of the patients overall, 24% of the tremor dominant patients, and 35% of the non-tremor dominant patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Parkinson’s Disease is a neurodegenerative disease characterized by motor and non-motor findings. Motor findings generally start with involvement of a single extremity and progress throughout life; asymmetrical involvement continues with clinical findings typically predominant in the first involved side. Parkinson’s Disease is divided into two phenotypes, tremor dominant, and non-tremor dominant.We aimed to investigate and compare the incidence of dyskinesia development and other clinical parameters such as age, gender, disease duration, and treatment between the tremor dominant and non-tremor dominant phenotypes of idiopathic Parkinson’s Disease.Methods: We conducted a retrospective study of 502 patients (183 females, 319 male) with idiopathic Parkinson’s Disease.Results: Two hundred eighty-five (56%) patients had tremor dominant phenotype and 217 (44%) had non-tremor dominant. Dyskinesia was observed in 29% of the patients overall, 24% of the tremor dominant patients, and 35% of the non-tremor dominant patients. Dyskinesia incidence was significantly greater in the non-tremor dominant group than the tremor dominant group (p=0.006). Average age at diagnosis in patients who developed dyskinesia 57±12.9 years and who did not 64±11.1 years. Thirty-four (24 tremor dominant, 10 non-tremor dominant) patients had a family member with Parkinson’s Disease. Thirteen patients (5 tremor dominant, 8 non-tremor dominant) with a positive family history developed dyskinesia. The incidence of dyskinesia development according to clinical phenotype was independent from family history and was greater in the NTD group (p=0.02). Levodopa treatment was received by 421 (83%) patients; the incidence of dyskinesia development who used levodopa was 33% (p

🔖

Cite This Article

ÖZTÜRK, Ü., ALTINAYAR, S., ADIGÜZEL, A. (2022). PREDICTING THE RISK OF DYSKINESIA DEVELOPMENT IN PARKINSON’S DISEASE. Türk Geriatri Dergisi, Cilt: 23 - Sayı: 2, 224–229. https://ajindex.com/articles/623587

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders 2011;26(3):399-406. (PMID: 21264941)
  2. Fernandez HH. 2015 Update on Parkinson disease. Cleve Clin J Med. 2015;82(9):563-8. (PMID:26366951)
  3. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson’s disease: A baseline analysis of the DATATOP cohort. Neurology 1990;40(10):1529- 34. (PMID:2215943)
  4. Kalia LV, Lang AE. Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD. Nature reviews Neurology 2016;12(2):65. (PMID:26782330)
  5. Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013;84(4):409-15. (PMID: 22952329)
  6. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature Reviews Neurology 2013;9(1):13. (PMID: 23183883)
  7. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. Journal of Neuropathology & Experimental Neurology 1991;50(6):743-55. (PMID:1748881)
  8. Van de Berg WD, Hepp DH, Dijkstra AA, Rozemuller JA, Berendse HW, Foncke E. Patterns of alphasynuclein pathology in incidental cases and clinical subtypes of Parkinson’s disease. Parkinsonism & related disorders 2012;18:S28-S30. (PMID:22166446)
  9. Lewis MM, Du G, Sen S, et al. Differential involvement of striato-and cerebello-thalamo-cortical pathways in tremor-and akinetic/rigid-predominant Parkinson’s disease. Neuroscience 2011;177:230-9. (PMID:21211551)
  10. Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson’s disease patients show different patterns of FP-CIT Single photon emission computed tomography. Movement Disorders 2011;26(3):416- 23. (PMID:21264942)
  11. Picconi B, Hernández LF, Obeso JA, Calabresi P. Motor complications in Parkinson’s disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Movement Disorders 2018;33(6):867-76. (PMID:29219207)
  12. Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annual review of neuroscience 2011;34:441-66. (PMID: 21469956)
  13. Zhang Y-h, Tang B-s, Song C-y, et al. The relationship between the phenotype of Parkinson’s disease and levodopa-induced dyskinesia. Neuroscience letters 2013;556:109-12. (PMID: 24135335)
  14. Kaasinen V, Kinos M, J